Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
News|Articles|October 1, 2024
177Lu-Dotatate Improves PFS in Recurrent Meningioma
Author(s)Ariana Pelosci
Fact checked by: Gina Mauro
Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.
Advertisement
Advertisement
The primary end point of progression-free survival (PFS) was met when 177Lutetium -Dotatate (Lutathera) was used to treat patients with refractory grade II/III meningioma, according to results from a phase 2 trial that was presented at the
Related to this article
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early-career physicians building new programs.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Advertisement
Advertisement